Novagali Pharma, an emerging ophthalmic pharmaceutical company, announced today orphan drug designation granted by the U.S. Food and Drug Administration (FDA) to Cyclosporine A drug Vekacia®, a patented cationic emulsion, for the treatment of Vernal Keratoconjunctivitis (VKC). VKC is a rare and severe form of chronic allergic conjunctivitis affecting mostly children and young adults. [click link for full article]
More...